Biolexis Therapeutics is a biotech company founded by two veterans of both small molecule drug development and life science startups. Cancer biologist Dr. David Bearss is an expert in small-molecule drug development and the use of genetic model systems in drug discovery while Dr. Hariprasad Vankayalapati, a medicinal chemist, brings extensive knowledge and experience in identifying and developing lead candidates for drug discovery. Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases.

Tags

Endocrinology and Metabolic Disease

Neoplasms

Other Diseases

Small molecule drug

Chemical drugs

Immune cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	11
Neoplasms	9
Nervous System Diseases	5
Hemic and Lymphatic Diseases	2
Immune System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	11
Chemical drugs	5
Immune cell therapy	2
Biological products	1
Degradable Molecular Glue	1

Top 5 Target	Count

HDAC6(Histone deacetylase 6)	3
TGM2(Protein-glutamine gamma-glutamyltransferase)	3
GLP-1R(Glucagon-like peptide 1 receptor)	2
CDK9(Cyclin-dependent kinase 9)	2
EIF2AK4(eukaryotic translation initiation factor 2 alpha kinase 4)	2

Drugs associated with Biolexis Therapeutics

MLX-7006

Target

GLP-1R

Mechanism

GLP-1R agonists

Active Org.

Biolexis Therapeutics

Originator Org.

Biolexis Therapeutics

Active Indication

Diabetes Mellitus, Type 2 [+1]

Inactive Indication-

Drug Highest PhaseIND Application

First Approval Ctry. / Loc.-

First Approval Date-

SLX 9000

Target

TGM2

Mechanism

TGM2 modulators

Active Org.

Signalexis, Inc.

Originator Org.

Signalexis, Inc.

Active Indication

Immune System Diseases [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

SLX 1046

Target

EIF2AK4

Mechanism

EIF2AK4 modulators

Active Org.

Signalexis, Inc.

Originator Org.

Signalexis, Inc.

Active Indication

Immune System Diseases [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

100 Clinical Results associated with Biolexis Therapeutics

0 Patents (Medical) associated with Biolexis Therapeutics

Literatures (Medical) associated with Biolexis Therapeutics

21 Apr 2025·Cancer Research

Abstract 4315: PELP1 oncogene targeted therapy for the treatment of ovarian cancer

Author: Vankayalapati, Hariprasad ; Sharma, Gaurav ; Tekmal, Rajeshwar R. ; Arnold, William C. ; Ebrahimi, Behnam ; Rao, Arhan ; Viswanadhapalli, Suryavathi ; Vadlamudi, Ratna K.

AbstractBackground:Ovarian cancer (OCa) is the most lethal of all gynecologic malignancies in the United States. Despite the initial responses observed in OCa patients to standard combinations of surgical and cytotoxic chemotherapy, roughly 80% of these patients will develop recurrence and ultimately succumb to chemotherapy-resistant disease. Novel targeted therapies for the treatment of OCa are needed. The oncogene PELP1 is highly expressed in a variety of cancers including OCa. The suppression of PELP1 is shown to reduce the proliferation of cancer cells and renders therapy-resistant cells more susceptible to chemotherapy. We have recently developed a novel inhibitor SMIP34 that binds and degrades PELP1. The purpose of this study is to evaluate the efficacy of SMIP34 in the treatment of OCa.Methods:We have used multiple established and patient-derived OCa models that represent all 4 types of OCa. SMIP34 was used for the inhibition of PELP1 oncogenic functions. The effect of SMIP34 on OCa cell viability was examined by MTT assays. The efficacy of SMIP34 on cell survival and apoptosis was determined using clonogenic assays, Annexin V/PI labelling and caspase 3/7 assays respectively. Mechanistic studies were performed using western blotting, RTq-PCR and RNA-seq analyses. The effect of SMIP34 on STAT3 signaling was examined using reporter gene assays. The efficacy of PELP1 inhibitor on tumor growth was examined using ex vivo patient derived explants (PDEX), patient-derived organoids (PDO), and in vivo patient-derived xenograft models (PDX).Results:Utilizing several established and primary OCa cells, we found that SMIP34 decreased cell viability, impaired colony formation capacity, and induced apoptosis. SMIP34 markedly diminished the viability of OCa cells resistant to carboplatin, cisplatin, and taxol. SMIP34 therapy reduced STAT3 reporter activity. Western blot analysis confirmed that treatment with SMIP34 decreased the phosphorylation of PELP1 regulated survival pathways including STAT3, mTOR and AKT. Mechanistically, SMIP34 interaction with PELP1 facilitates its degradation along with its associated protein complex, which includes TEX10, LAS1L, and SENP3. Biochemical analysis confirmed that SMIP34 decreased ribosome biogenesis and new protein synthesis. RT-qPCR demonstrated that SMIP34 therapy decreases the expression of PELP1 target genes. RNA-seq analysis indicated that SMIP34 therapy downregulated cell cycle genes and induced apoptosis. Utilizing PDEX and PDO ex vivo, assays we show that SMIP34 markedly reduced tumor proliferation as assessed by Ki67 staining. Moreover, SMIP34 (20 mg/kg/IP) administration in vivo markedly inhibited tumor progression in patient-derived xenografts.Conclusions:Collectively our results using in vitro, ex vivo, and in vivo models suggest that SMIP34 may serve as potential therapeutic for treating OCa by inhibiting PELP1 oncogenic signaling.Citation Format:Gaurav Sharma, Behnam Ebrahimi, Arhan Rao, William C. Arnold, Hariprasad Vankayalapati, Rajeshwar R. Tekmal, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi. PELP1 oncogene targeted therapy for the treatment of ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4315.

05 Apr 2024·Cancer Research

Abstract LB161: Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC)

Author: Bearss, David J. ; Li, Zhaoliang ; Vankayalapati, Hariprasad ; Medley, Kyle ; Lin, Chenyu

AbstractBackground: The use of new potent targeted therapies in prostate cancers has led to the resistance and development of highly aggressive variant prostate cancers (AVPC), including neuroendocrine prostate cancers (NEPC). N-MYC and C-MYC oncogenes overexpress in all aggressive prostate cancers (PCa). This overexpression is highly prevalent in these lethal subtypes of cancers, detected in 2% of all Prostate Cancers and over 10-17% of mCRPC patients. Transcriptional targets of CDK9 are MYCs, which act as an oncogenic driver, sufficient to transform human-derived prostate cancer cells to take on AVPC and NEPC phenotypic changes. Additionally, N-MYC and C-MYC play key roles in tumor drug resistance, and their downregulation, through CDK9 inhibition or degradation lowers tumor growth. Our efforts have demonstrated that targeting drivers of NEPC and mCRPC with highly selective CDK9 molecular glue degraders SLX-3064 SLX-3065 was designed from reversible SLX-3039 for therapeutic intervention of mCRPC, AVPC, and NEPCs.Materials and Methods: We employed our MolecuLernTM-trained molecular glue library design strategies and in vitro CDK9 kinase binding assays. Other experiments include cellular efficacies of single-agent Molecular Glue degraders and their effect in combination experiments on 22Rv1, LASCPC-01, C4-2, and C4-2B MYC expressed PCa cells. Kinase selectivity, Nano BRET, ADME-Tox, in vitro safety, secondary pharmacological assays, Cell engraftment mouse tumor mode, and PK studies were performed.Results: We designed and synthesized a series of novel small molecule CDK9 Molecular Glue degraders based on our initial CDK9 inhibitor lead SLX-3030 and SLX-3039. The SLX-3064 and SLX-3065 reversibly bind to CDK9 with an IC50 of 9 and 7 nM in kinase binding, in target engagement assays, elicit pharmacological responses in N-MYC, C-MYC, driven prostate cancer cells in vitro in LASCPC-01 (21, 35 nM), 22Rv1 (108, 236 nM), C4-2B (15, 12 nM), C4-2 (2.7, 1.5 nM) and VCap (86, 73 nM) cell lines. SLX-3064 and SLX-3065 exhibited potent activity degrading total, pCDK9, MYCs, Mcl-1, and its downstream RNA Pol II, Ser 2, 5, 7, and pAR Ser-81 in a dose-dependent manner. Additionally, we performed in vitro ADME-Tox, hERG, P450, safety panel screen, and in vivo PK experiments in rodent and beagle dog species.Conclusion: In summary, both SLX-3064 and SLX-3065 molecular glues display complete degradation of CDK9 and its downstream markers, and these degraders possess ideal developable criteria as oral agents. With these characteristics, SLX-3065 was selected as a candidate that had the appropriate developable properties and our plans for conducting additional IND-enabling studies and future clinical trial plans will also be discussed.Citation Format: Chenyu Lin, Zhaoliang Li, Kyle Medley, David J. Bearss, Hariprasad Vankayalapati. Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB161.

05 Apr 2024·Cancer Research

Abstract LB444: Identification of a novel and selective Transglutaminase 2 (TGM2) inhibitors modulate tumor microenvironment in Glioblastoma

Author: Medley, Kyle ; li, Zhaoang ; Bearss, David J. ; Vankayalapati, Hariprasad ; Lin, Chenyu

AbstractBackground: TGM (Transglutaminase) family enzymes are Ca2+ dependent and engaged in specific posttranslational modifications by cross-linking extracellular matrix (ECM) proteins. ECM protein complex is more stable and resistant to enzymatic degradation. These enzymes modify proteins by cross-linking epsilon-(gamma-glutamyl), lysine, or (gamma-glutamyl) polyamine bonds. TGM2 (Transglutaminase 2) is a ubiquitous enzyme, and its expression is identified in the cytoplasm, plasma membrane, and the nucleus of various cells. The membrane-bound form of TGM2 binds GTP and functions as a G protein. TGM2 regulates cell survival, proliferation, migration, and modulation through ECM organization. We explored the role of TGM2 in Glioblastoma cells and its role in modulating the tumor microenvironment, cell proliferation, and survival. In addition to TGM2's role in GBM tumors, its expression has been linked to resistance to certain therapies in glioblastoma was investigated. Targeted modulation of macrophages with TGM2 inhibitors impacts the immune response against GBM, potentially enhancing the efficacy. Understanding the intricate interplay between TGM2, and GBM-associated macrophages is a key component of the tumor microenvironment (TME) and crucial for the development of targeted TGM2 inhibitors.Materials and Methods: Human Transglutaminase 2 (hTGM2) activity of inhibitors was assayed using the fluorescent transamination assay incorporating dansylcadaverine into glutamine-donor substrate N, N-dimethyl casein, and DCC. Cellular efficacies of selected TGM2 inhibitors evaluated in U138 and U87 glioblastoma cells in CellTiter-Glo Luminescent cell viability assay.Results: We have identified a series of novel small molecule TGM2 inhibitors based on our initial lead fragment hits with an IC50s 6-29 uM from our in-house MolecuLern fragment library. Fragments2Lead (F2L) optimizations strategies, synthesis, and SAR studies provided a lead SLX-9029 and SLX-9031 inhibitors with IC50s of 1.2, 1.5 uM in inhibiting TGM2 activity in our established cell-free fluorescent transamination assay. The initial TMG2 inhibitor leads further screening for TGM2-expressed U138 and U87 glioblastoma cells demonstrating promising cellular efficacies as singles agents. Additional GBM cell profiling, combination studies along with safety secondary pharmacology, cellular toxicities, and PK results will be discussed.Conclusion: In summary, we identified promising lead TGM2 inhibitors that show activity in both cell-free and cell-based TGM2-expressed GMB cells. The TGM family members, selectivity, additional GBM cellular profiling, ADME, cellular toxicity, and in vivo PK studies are underway, and these results will be presented.Citation Format: Hariprasad Vankayalapati, Chenyu Lin, Zhaoang li, Kyle Medley, David J. Bearss. Identification of a novel and selective Transglutaminase 2 (TGM2) inhibitors modulate tumor microenvironment in Glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB444.

News (Medical) associated with Biolexis Therapeutics

14 Mar 2025

·www.prnewswire.com

Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor Activation

CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLern™ AI-Driven Discovery LEHI, Utah, March 14, 2025 /PRNewswire/ -- Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of the cryo-electron microscopy (cryoEM) structure of BLX-7006, its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor, distinct from any previously known approaches. The cryoEM structural confirmation validates the predictive power of MolecuLern, Biolexis' AI-enabled drug discovery platform. MolecuLern identified BLX-7006 as a novel small molecule capable of allosterically modulating GLP-1 receptor activity. Unlike many oral small-molecule GLP-1 therapies being developed—whose compounds are almost exclusively modified analogs of existing molecules such as Pfizer's Danuglipron and Eli Lilly's Orforglipron—BLX-7006 is a brand-new chemotype with an entirely unique binding mode. "The cryoEM structural confirmation of BLX-7006 provides definitive proof that we have discovered a new way to activate the GLP-1 receptor allosterically," said Dr. Hariprasad Vankayalapati, Chief Scientific Officer of Biolexis Therapeutics. "This isn't just an incremental improvement on existing compounds—it's a new mechanism enabled by our AI-driven approach to drug discovery. With superior metabolic stability and a more efficient synthesis process, BLX-7006 represents a breakthrough in the quest for next-generation, oral GLP-1 therapies." Biolexis is actively completing the toxicology and manufacturing studies necessary to support human clinical testing of BLX-7006. With these critical studies underway, the company plans to initiate first-in-human trials in Q3 2025, marking a major step toward bringing this novel therapy to patients with obesity, type 2 diabetes, and metabolic dysfunction. Asked to provide additional details on Biolexis' AI drug discovery platform, Vankayalapati stated, "MolecuLern integrates AI-driven molecular design, wet lab validation, and proprietary structural modeling to identify innovative small molecules for challenging drug targets. The successful cryoEM validation of BLX-7006's novel binding mode underscores the ability of MolecuLern to accurately predict molecular interactions and accelerate the discovery of first-in-class therapeutics." About Biolexis Therapeutics Biolexis Therapeutics is a biopharmaceutical company pioneering the discovery and development of next-generation metabolic drugs to address chronic diseases such as obesity and type 2 diabetes. Its proprietary AI-enabled drug discovery platform, MolecuLern, drives the rapid identification of novel small-molecule therapies, delivering superior efficacy and safety profiles. With a commitment to scientific excellence and patient-centered innovation, Biolexis is redefining the future of metabolic medicine. For more information, visit biolexistx.com. SOURCE Biolexis Therapeutics Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

09 Dec 2024

·www.prnewswire.com

Biolexis Therapeutics Announces Positive Results from Expanded Diet Induced Obesity (DIO) Model Study for BLX-7006

Study Demonstrates 16.6 % at day 7 to 29 % on terminal day 28 Weight Loss and Superior Efficacy Compared to peptide-based approved or clinical stage oral Obesity Drugs in the DIO Model LEHI, Utah, Dec. 9, 2024 /PRNewswire/ -- Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives of patients with chronic metabolic conditions, including obesity, diabetes, and related diseases, today announced the successful completion of an expanded diet -induced obesity (DIO) trial for its candidate drug, BLX-7006. The results demonstrate significant weight loss and superior efficacy compared to leading obesity therapies, including Semaglutide and Orforglipron, providing robust support for BLX-7006's potential as a transformative treatment for obesity & diabetic indications. The newly completed study builds upon a previous DIO study in which BLX-7006 demonstrated a promising 15.6 % weight loss. In the expanded study, BLX-7006 achieved a substantial 29% weight loss, attributed to evaluating higher dosage levels. These higher doses were well tolerated, with no observed toxicity, marking an important milestone in the development of BLX-7006 for obesity management. "We are extremely encouraged by the results of our expanded DIO study, which show a significant improvement in weight loss with BLX-7006 compared to our initial study," said Dr. Hariprasad Vankayalapati, Chief Scientific Officer at Biolexis Therapeutics. "The higher dosage levels are well tolerated, have yielded a 29% weight loss, which is not only a strong indication of the potential therapeutic benefits of BLX-7006, but also underscores its safety profile, with no evidence of toxicity at these elevated doses in non-clinical animal models. Our findings place BLX-7006 in a competitive position in the obesity treatment space." In addition to the DIO study, Biolexis has completed a non-human primate study to assess BLX-7006's oral bioavailability profile. The study demonstrated high exposure levels, further validating BLX-7006's potential translation into future human clinical trials. "These results are a testament to the strength of our BLX-7006 program and the dedication of our team in developing novel metabolic therapeutics," said Keith Marmer, Chief Business Officer of Biolexis Therapeutics. "With the growing global prevalence of obesity and related metabolic disorders, there is a pressing need for more effective oral treatments over current injectables. The compelling results from both our expanded DIO study and the non-human primate study position BLX-7006 as a promising future clinical candidate to address this critical unmet need." Biolexis will present these findings and additional data at the upcoming Innovation in Obesity Therapeutics Summit in San Diego, CA, on December 11-12, 2024. Biolexis Co-founder Dr. David Bearss will present the latest data on BLX-7006's efficacy and its potential to provide a safe, effective, and oral alternative for patients struggling with obesity and related metabolic conditions. "We are excited to share these groundbreaking results with the scientific community at the Innovation in Obesity Therapeutics Summit," said Dr. Bearss. "As we continue to advance BLX-7006 through clinical development, we remain committed to improving patient outcomes and bringing innovative solutions to the market that can have a meaningful impact on the lives of those affected by chronic metabolic diseases." About Biolexis Therapeutics Biolexis Therapeutics is a biopharmaceutical company focused on discovering and developing innovative metabolic drugs to address chronic diseases such as obesity, diabetes, and related conditions. The company's pipeline includes novel small-molecule oral therapies designed to improve patient outcomes with enhanced efficacy and safety profiles. Biolexis is committed to advancing the treatment of chronic metabolic disorders to enhance patients' lives worldwide. For more information about Biolexis Therapeutics and its pioneering research, please visit biolexistx.com. Forward-Looking Statements This press release contains forward-looking statements regarding the clinical development of BLX-7006, including its potential safety, efficacy, and market positioning. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially from those anticipated due to various factors, including clinical trial results, regulatory approval, and market conditions. SOURCE Biolexis Therapeutics Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

04 Dec 2024

·www.businesswire.com

Healthcare Industry Digital Transformation and Emerging Technologies Analysis Report 2024: Professionals are Prioritizing AI for Current and Future Investments - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Digital Transformation and Emerging Technologies in the Healthcare Industry 2024 Edition" report has been added to ResearchAndMarkets.com's offering. The report examines the progress of digital transformation in the pharmaceutical industry. It assesses the industry's preparedness to embrace innovation, explores the challenges and opportunities associated with digital transformation as well as highlights current and emerging trends in technology-related investments. The pharmaceutical industry is facing ongoing shifts driven by declining profit margins, increasing cost pressures, and the need to both replenish pipelines and maximize peak sales, all while adhering to strict regulatory and legislative requirements. Although adopting innovative technologies is seen as a key strategy to mitigate these challenges, the digitalization process is complex, time-consuming, and requires significant investment, along with sustained commitment and transparent dialogue with various stakeholders, including employees, investors, and regulators. The pharmaceutical industry is experiencing steady advancement in digital transformation. Mirroring 2023 survey findings, operations enablement and innovation was selected as the main scope of digital transformation in 2024. Optimism regarding the growth of digital transformation in their organizations reached record highs among the pharma industry professionals. In line with previous years' results, lack of specific skills and talents was selected as the top hinderance for digital transformation. Digital privacy and data security issues have ranked as the top concern associated with digital transformation, closely followed by cybersecurity concerns. Strong leadership was regarded as the key driver for a successful digital transformation. Pharma industry professionals are prioritizing artificial intelligence (AI) for current and future investments. Digital transformation is a must for maintaining competitive advantage in the pharmaceutical industry. Scope Benchmark the level of business readiness and technology adoption. Gain a deeper understanding of the business functions affected the most by digital transformation. Identify and assess barriers to adopting emerging technologies. Define the critical requirements for success. Determine the importance of emerging technologies to the pharmaceutical industry. Evaluate current levels of investment and identity both present and future investment priorities. Analyze the impact of COVID-19, inflation, and other factors on digitalization efforts. Explore the impact of emerging technologies on the pharmaceutical value chain. Assess the role of digital transformation in sustaining competitive advantage. Reasons to Buy Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have in the near future. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector. Develop business strategies by understanding the key factors of digital transformation and emerging technology in the healthcare sector. Identify emerging industry trends in the uptake of emerging technologies to gain a competitive advantage. Key Topics Covered: Study Design Key Findings Overview of Digital Transformation Digital Transformation Strategies Digital Transformation Objectives Obstacles to Digital Transformation Concerns Associated with Digital Transformation Necessities for Digital Transformation Emerging Technologies - Investment Trends Artificial Intelligence Case Studies Summary of Key Findings Appendix Competitive Landscape Amgen AB BenevolentAI Ltd Biolexis Therapeutics Inc Cellix Biosciences Inc Eli Lilly and Co Generate Biomedicines Inc Google Cloud Platform Hackensack Meridian Health Inc Healx Ltd Highmark Health InSilico Medicine Mount Sinai Health System Novartis AG Recursion Pharmaceuticals Inc For more information about this report visit https://www.researchandmarkets.com/r/r3umsv About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 Deals associated with Biolexis Therapeutics

100 Translational Medicine associated with Biolexis Therapeutics

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 06 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

IND Application

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MLX-7006 ( GLP-1R )	Obesity More	IND Application
SLX 3030 ( CDK9 )	Castration-Resistant Prostatic Cancer More	Preclinical
SLX 9000 ( TGM2 )	Immune System Diseases More	Preclinical
MLX4000 ( TNIK )	Diabetes Mellitus, Type 2 More	Preclinical
MLX 0800 ( AMPK )	Obesity More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis